P3.02b-079 Effects of Icotinib with and without Radiation Therapy on Patients with EGFR Mutant Non-Small Cell Lung Cancer and Brain Metastases

Abstract

activating EGFR mutation. Details of the 22 patients harboring the EGFR T790M mutation are listed in Table 1. The response rate to chemotherapy was 12.5% (best response; 1 PR, 4 SD and 3 PD) and the median time to progression (TTP) was 3.0 months. The response rate to EGFR TKIs treatment was 8.3% (best response; 1 PR, 3 SD and 8 PD), and the median TTP was 2.7 months. Three patients were treated with third generation EGFR TKIs (osimertinib or ASP 8237) and all achieved partial response (TTP; 33.3, 13.6 and 3.5 months, respectively). Conclusion: De novo EGFR T790M mutation is a rare event even in EGFR mutant NSCLC and associated with unfavorable clinical outcome to chemotherapy and EGFR TKIs.